Mark Cziraky, PharmD, CLS: Challenges in the US Biosimilars Market

Mark Cziraky, PharmD, CLS, vice president of research for Healthcore, describes challenges in the US biosimilars market.

Transcript:

Well I think one of the biggest challenges is the level of—the number of biosimilars that are being approved in the market. I mean, we’re seeing 10 now [approved] to date* and we’re going to see another 10 hopefully this year; a total of 20. But comparable to Europe, there’s 41 now approved ex-US, so we have a lot of room to catch up. In addition to that, the actual marketing of the products is a lot slower than was anticipated, so, with those that are already approved, only 3 are currently available on the market. So, the amount of market penetration, the amount of cost reduction that we’re able to see currently with those therapies is quite limited.

*as of the date of filming.

Related Videos
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
andre harvin
Andre Harvin, PharmD
Christine Baeder
Christine Baeder Smiling
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Related Content
© 2023 MJH Life Sciences

All rights reserved.